Journey Medical Corp. (DERM)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$7.86-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Intact: The reason to own it still holds.
Journey Medical aims to grow revenue above $16 million in 2026. Cash from operations turned positive at $2.9 million in Q1 2026. The company is stabilizing after losses and improving cash flow. Analysts expect revenue growth of about 66% next year.
The company is still loss-making with negative free cash flow overall. Revenue declined slightly from $16.08 million in Q4 2025 to $15.96 million in Q1 2026. Past earnings misses and elevated risk raise doubts about sustained recovery.
The stock trades about 49% below our fair value near $14. Analysts expect 66% revenue growth, which seems optimistic given recent declines and losses. Our view is cautious on execution and cash flow sustainability.
Breaks if: Cash from operating activities turns negative over next 4 quarters
Enhance cash generation to support financial performance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation, as DERM is focused on driving revenue growth while currently operating at a loss. The company's recent financial performance has been strong, but it faces high risks in a competitive healthcare sector.
The market appears to have priced in a justified valuation, with expectations that align closely with current performance. There is a low level of fragility in the stock, suggesting that the current valuation reflects the company's recent stability and growth potential.
Management is prioritizing revenue growth and expanding payer access, which has shown progress in recent quarters. However, the company remains loss-making, and while cash generation has improved, it is still a key area to watch for future stability.
The long-term thesis depends on management's ability to maintain revenue growth and expand payer access for Emrosi. Additionally, external factors such as sector performance and economic conditions will play a significant role in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company reported strong revenue growth, driven by Emrosi's traction. Payer access for Emrosi is expanding, which supports further revenue growth. Recent earnings beat estimates, reinforcing the positive outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS falls below $0.07 in FY 2026
Breaks if: Revenue falls below $16 million in FY 2026
Continue to grow total net revenues, driven by commercial demand momentum for Emrosi and expanding payer access.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $13.1 million in 2025-Q1 to $16.0 million in 2026-Q1 (+21% YoY) and further to $18.5 million in 2026-Q2 (+23% YoY). Management consistently emphasizes revenue growth driven by Emrosi demand and expanding payer access, and the financials show delivering growth.
“We delivered solid performance in the second quarter, highlighted by 23% total net revenue growth, year over year.”
“Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million.”
“Our third quarter 2025 results reflect continued strong execution and accelerating commercial momentum, with revenue increasing 21% year-over-year to $17.6 million.”
Overall, DERM's multi-year view is contingent on effective execution of its growth strategies and favorable market conditions. Not investment advice.